NCT07087860

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: RECRUITING

Phase: PHASE2

Sponsor: Mayo Clinic

Condition: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.